Circulation, Vol 71, 1113-1120, Copyright © 1985 by American Heart Association
A Edlund, B Berglund, D van Dorne, L Kaijser, J Nowak, C Patrono, A Sollevi and A Wennmalm
The present investigation was undertaken to study cardiac release of
adenosine and prostacyclin (prostaglandin [PG] I2) in patients with
ischemic heart disease (IHD), and to assess coronary vascular resistance
before and after inhibition of synthesis in such patients. In 48 patients
with IHD, arterial and coronary sinus blood samples were taken at rest,
during atrial pacing to angina, and after pacing. Levels of purines were
determined by high-performance liquid chromatography and the PGI2
metabolite 6-keto-PGF1 alpha was measured with radioimmunoassay. Coronary
sinus blood flow was determined with retrograde continuous thermodilution
before and after oral administration of indomethacin, aspirin, naproxen, or
ibuprofen. Atrial pacing induced myocardial ischemia, as evidenced by
typical chest pain and arrested lactate extraction. Adenosine was extracted
at rest, but during ischemia there was a significant release of its
metabolite hypoxanthine, indicating increased myocardial breakdown of
high-energy adenine nucleotides. Arterial and coronary sinus concentrations
of 6- keto-PGF1 alpha were low and no significant differences between them
were found. After administration of the PG-synthesis inhibitor
indomethacin, coronary vascular resistance was elevated, as was the cardiac
oxygen extraction. The three other PG-synthesis inhibitors (aspirin,
naproxen, and ibuprofen) did not, however, induce any change in coronary
vascular resistance or in the cardiac extraction of oxygen. On the basis of
these data we suggest that in patients with IHD cardiac ischemia results in
increased myocardial production and release of purines, cardiac ischemia
does not elicit any detectable increase in coronary production of
prostacyclin, and the increased coronary resistance induced by indomethacin
does not reflect the involvement of locally formed PG in the maintenance of
coronary flow, but is rather a direct effect of the drug.
ARTICLES
Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation
This article has been cited by other articles:
![]() |
J. D. Tune, M. W. Gorman, and E. O. Feigl Matching coronary blood flow to myocardial oxygen consumption J Appl Physiol, July 1, 2004; 97(1): 404 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Merkus, B. Houweling, A. Zarbanoui, and D. J. Duncker Interaction between prostanoids and nitric oxide in regulation of systemic, pulmonary, and coronary vascular tone in exercising swine Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1114 - H1123. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Voelkel, K. M. Wynne, D. B. Badesch, B. M. Groves, and N. F. Voelkel Hyperuricemia in Severe Pulmonary Hypertension* Chest, January 1, 2000; 117(1): 19 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Duffy, S. F. Castle, R. W. Harper, and I. T. Meredith Contribution of Vasodilator Prostanoids and Nitric Oxide to Resting Flow, Metabolic Vasodilation, and Flow-Mediated Dilation in Human Coronary Circulation Circulation, November 9, 1999; 100(19): 1951 - 1957. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Minton and J. A. Henry Pharmacodynamic Interactions Between Infused Adenosine and Oral Theophylline Human and Experimental Toxicology, January 1, 1991; 10(6): 411 - 418. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |